Miravant Medical Technologies (OTCMKTS:MRVT) & Harrow (NASDAQ:HROW) Head-To-Head Survey

Miravant Medical Technologies (OTCMKTS:MRVT) and Harrow (NASDAQ:HROW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Miravant Medical Technologies and Harrow’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Miravant Medical Technologies	N/A	N/A	N/A
Harrow	-4.49%	-2.18%	-0.35%

Analyst Ratings

This is a summary of current ratings and price targets for Miravant Medical Technologies and Harrow, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Miravant Medical Technologies	0	0	0	0	0.00
Harrow	0	0	7	1	3.13

Harrow has a consensus target price of $64.67, indicating a potential upside of 74.82%. Given Harrow’s stronger consensus rating and higher probable upside, analysts plainly believe Harrow is more favorable than Miravant Medical Technologies.

Valuation & Earnings

This table compares Miravant Medical Technologies and Harrow”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Miravant Medical Technologies	N/A	N/A	N/A	N/A	N/A
Harrow	$199.61 million	6.86	-$17.48 million	($0.25)	-147.96

Miravant Medical Technologies has higher earnings, but lower revenue than Harrow.

Institutional & Insider Ownership

72.8% of Harrow shares are held by institutional investors. 17.1% of Miravant Medical Technologies shares are held by insiders. Comparatively, 13.7% of Harrow shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Harrow beats Miravant Medical Technologies on 6 of the 10 factors compared between the two stocks.

About Miravant Medical Technologies

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.